GoodRx turns Wegovy into a self-pay pitch

New GLP-1, same old scramble

GoodRx is back in the middle of the GLP-1 feeding frenzy, this time by rolling out access to Novo Nordisk’s Wegovy HD for eligible self-pay patients. The pitch is simple: if you’re paying cash, GoodRx wants to make the process less annoying and a little more predictable.

The money part

Here’s the setup:

• Wegovy HD is priced at $399 per month for eligible self-pay patients
• A two-month supply runs $798
• A three-month supply comes in at $1,197

That doesn’t make it cheap, obviously. But in GLP-1 land, “clear pricing” is basically a love language. And for GoodRx, every new branded medication it helps route through its platform is another chance to stay useful in a market where patients are hunting for access like it’s concert tickets.

Why investors are watching

GoodRx has spent years trying to be the toll booth between consumers and the pharmacy counter. The more high-demand drugs it can help surface, price, and distribute, the more valuable that position gets. And with obesity drugs still pulling in massive interest, even incremental access wins can matter.

There’s also a broader theme here: GoodRx is leaning hard into cash-pay healthcare, where patients are often less interested in insurance drama and more interested in “just tell me what it costs.” That’s not flashy, but it can be sticky.

Big picture

Novo Nordisk gets another way to broaden Wegovy access. GoodRx gets another reason for people to show up. And investors get a reminder that sometimes the boring middleman can still make money when everyone else is fighting over the shiny new drug.